HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer

被引：0
|
作者：
Hamilton, Erika P.
Martin, Miguel
O'Sullivan, Ciara Catherine
Curigliano, Giuseppe
Sohn, Joohyuk
Tsurutani, Junji
Tryfonidis, Konstantinos
Santarpia, Libero
Yang, Shan
Dieras, Veronique
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashiville, TN USA
[2] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[3] Mayo Clin, Rochester, MN USA
[4] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[5] Yonsei Canc Ctr, Seoul, South Korea
[6] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan
[7] Merck & Co Inc, Rahway, NJ 07065 USA
[8] Seagen Inc, Bothell, WA USA
[9] Ctr Eugene Marquis, Rennes, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1115
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+metastatic breast cancer progressing on trastuzumab therapy
    O'Shaughnessy, J.
    Blackwell, K. L.
    Burstein, H.
    Storniolo, A. M.
    Sledge, G.
    Baselga, J.
    Koehler, M.
    Laabs, S.
    Florance, A.
    Roychowdhury, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [23] Cost-effectiveness of pertuzumab in HER2+metastatic breast cancer
    Qian, Y.
    Durkee, B. Y.
    Pollom, E. L.
    King, M.
    Dudley, S. A.
    Shaffer, J. B.
    Chang, D. T.
    Gibbs, I. C.
    Goldhaber-Fiebert, J. D.
    Horst, K. C.
    CANCER RESEARCH, 2016, 76
  • [24] Phase I/II trial of ruxolitinib in combination with trastuzumab in HER2+metastatic breast cancer (MBC)
    Kalinsky, Kevin
    Lee, Shing
    Tiersten, Amy
    Makower, Della F.
    Cigler, Tessa
    Franks, Lauren
    Mundi, Prabhjot
    Chi, Dow-Chung
    Blumberg, Lauren
    Sender, Naomi
    Galazyn, Magdalena
    Hosi, Kristina
    Goel, Anupama
    Klein, Paula
    Andreopoulou, Eleni
    Sparano, Joseph
    Crew, Katherine D.
    Califano, Andrea
    Silva, Jose
    Hershman, Dawn L.
    CANCER RESEARCH, 2020, 80 (04)
  • [25] Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status
    Hamilton, Erika
    Reinisch, Mattea
    Loi, Sherene
    Okines, Alicia
    Pohlmann, Paula R.
    Brix, Eva Harder
    Bourgeois, Hugues
    Yeo, Belinda
    Aylesworth, Cheryl
    Cobleigh, Melody
    Goncalves, Anthony
    Moroose, Rebecca
    Tkaczuk, Katherine H. R.
    Tsai, Michaela
    Simmons, Christine
    Andersson, Michael
    Soliman, Hatem
    Cairo, Michelina
    Carey, Lisa A.
    Cameron, David
    Ramos, Jorge
    Feng, Wentao
    Oliveira, Mafalda
    CANCER RESEARCH, 2021, 81 (04)
  • [26] Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
    Okines, Alicia F. C.
    Curigliano, Giuseppe
    Mizuno, Nobumasa
    Oh, Do-Youn
    Rorive, Andree
    Soliman, Hatem
    Takahashi, Shunji
    Bekaii-Saab, Tanios
    Burkard, Mark E.
    Chung, Ki Y.
    Debruyne, Philip R.
    Fox, Jenny R.
    Gambardella, Valentina
    Gil-Martin, Marta
    Hamilton, Erika P.
    Monk, Bradley J.
    Nakamura, Yoshiaki
    Nguyen, Danny
    O'Malley, David M.
    Olawaiye, Alexander B.
    Pothuri, Bhavana
    Reck, Martin
    Sudo, Kazuki
    Sunakawa, Yu
    Van Marcke, Cedric
    Yu, Evan Y.
    Ramos, Jorge
    Tan, Sherry
    Bieda, Mark
    Stinchcombe, Thomas E.
    Pohlmann, Paula R.
    NATURE MEDICINE, 2025, : 909 - 916
  • [27] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
    Murthy, R. K.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Lin, N. U.
    Borges, V.
    Abramson, V.
    Anders, C.
    Bedard, P. L.
    Oliveira, M.
    Jakobsen, E.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Braga, S.
    Duhoux, F. P.
    Greil, R.
    Cameron, D.
    Carey, L. A.
    Curigliano, G.
    Gelmon, K.
    Hortobagyi, G.
    Krop, I.
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Palanca-Wessels, M. C.
    Walker, L.
    Feng, W.
    Winer, E. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 597 - 609
  • [28] Bevacizumab plus trastuzumab for treatment of HER2+metastatic breast cancer
    De Amuriza Chicharro, N.
    Gastalver Martin, C.
    Goyache Goni, M. P.
    Cortijo Cascajares, S.
    Garcia Munoz, C.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 984 - 985
  • [29] Tucatinib vs Placebo, Both Combined With Capecitabine and Trastuzumab, for Patients With Pretreated HER2-Positive Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 4 - 7
  • [30] Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)
    Murthy, Rashmi
    Loi, Sherene
    Okines, Alicia
    Paplomata, Elisavet
    Hamilton, Erika
    Hurvitz, Sara
    Lin, Nancy
    Borges, Virginia
    Abramson, Vandana Gupta
    Anders, Carey
    Bedard, Philippe L.
    Oliveira, Mafalda
    Jakobsen, Erik
    Bachelot, Thomas
    Shachar, Shlomit S.
    Mueller, Volkmar
    Braga, Sofia
    Duhoux, Francois P.
    Greil, Richard
    Cameron, David
    Carey, Lisa
    Curigliano, Giuseppe
    Gelmon, Karen
    Hortobagyi, Gabriel
    Krop, Ian
    Loibl, Sibylle
    Pegram, Mark
    Slamon, Dennis
    Palanca-Wessels, Maria Corinna
    Walker, Luke
    Feng, Wentao
    Winer, Eric
    CANCER RESEARCH, 2020, 80 (04)
12345